Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $53.73 in the prior trading day, Conmed Corp (NYSE: CNMD) closed at $54.36, up 1.17%. In other words, the price has increased by $1.17 from its previous closing price. On the day, 0.23 million shares were traded. CNMD stock price reached its highest trading level at $55.045 during the session, while it also had its lowest trading level at $53.585.
Ratios:
Our goal is to gain a better understanding of CNMD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 49.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.35. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.88.
On April 28, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $55.
JP Morgan Downgraded its Overweight to Neutral on February 06, 2025, whereas the target price for the stock was revised from $85 to $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 07 ’25 when Garner Todd W sold 598 shares for $52.45 per share. The transaction valued at 31,365 led to the insider holds 0 shares of the business.
Garner Todd W bought 598 shares of CNMD for $31,365 on Aug 07 ’25. On May 05 ’25, another insider, Farkas Charles, who serves as the Director of the company, sold 4,000 shares for $56.94 each. As a result, the insider received 227,768 and left with 16,346 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNMD now has a Market Capitalization of 1682713856 and an Enterprise Value of 2530601728. As of this moment, Conmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.35, and their Forward P/E ratio for the next fiscal year is 11.46. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.27 while its Price-to-Book (P/B) ratio in mrq is 1.68. Its current Enterprise Value per Revenue stands at 1.908 whereas that against EBITDA is 11.499.
Stock Price History:
The Beta on a monthly basis for CNMD is 1.19, which has changed by -0.23608768 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, CNMD has reached a high of $78.19, while it has fallen to a 52-week low of $46.00. The 50-Day Moving Average of the stock is 4.06%, while the 200-Day Moving Average is calculated to be -9.78%.
Shares Statistics:
The stock has traded on average 451.78K shares per day over the past 3-months and 306180 shares per day over the last 10 days, according to various share statistics. A total of 30.95M shares are outstanding, with a floating share count of 30.07M. Insiders hold about 2.86% of the company’s shares, while institutions hold 111.62% stake in the company. Shares short for CNMD as of 1755216000 were 1980079 with a Short Ratio of 4.38, compared to 1752537600 on 2110069. Therefore, it implies a Short% of Shares Outstanding of 1980079 and a Short% of Float of 8.74.
Dividends & Splits
In the trailing 12 months, CNMD’s forward annual dividend rate was 0.8, compared to 0.80 this year. Against a Trailing Annual Dividend Yield of 0.014889262The stock’s 5-year Average Dividend Yield is 0.89. The current Payout Ratio is 18.82% for CNMD, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2001-09-10 when the company split stock in a 3:2 ratio.
Earnings Estimates
The dynamic stock of Conmed Corp (CNMD) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $1.32, with high estimates of $1.36 and low estimates of $1.27.
Analysts are recommending an EPS of between $4.5 and $4.43 for the fiscal current year, implying an average EPS of $4.47. EPS for the following year is $4.78, with 6.0 analysts recommending between $4.99 and $4.5.
Revenue Estimates
6 analysts predict $334.76M in revenue for the current quarter. It ranges from a high estimate of $337.3M to a low estimate of $332.5M. As of the current estimate, Conmed Corp’s year-ago sales were $316.7MFor the next quarter, 6 analysts are estimating revenue of $369.1M. There is a high estimate of $370.7M for the next quarter, whereas the lowest estimate is $367.69M.
A total of 6 analysts have provided revenue estimates for CNMD’s current fiscal year. The highest revenue estimate was $1.37B, while the lowest revenue estimate was $1.37B, resulting in an average revenue estimate of $1.37B. In the same quarter a year ago, actual revenue was $1.31BBased on 6 analysts’ estimates, the company’s revenue will be $1.44B in the next fiscal year. The high estimate is $1.46B and the low estimate is $1.42B.
